Trioxifene

Trioxifene

Trioxifene is a selective estrogen receptor modulator (SERM) that has been studied for the treatment of breast cancer and osteoporosis. It is structurally related to tamoxifen, another SERM that is widely used for the treatment of breast cancer.

Chemistry

Trioxifene is a nonsteroidal compound that is structurally similar to other SERMs such as tamoxifen and raloxifene. It has a triphenylethylene core structure, which is common among SERMs. The compound has two hydroxyl groups, which are thought to be critical for its estrogen receptor binding activity.

Pharmacology

Trioxifene acts as an antagonist at estrogen receptors in breast tissue, blocking the effects of estrogen and thereby inhibiting the growth of estrogen-dependent breast cancer cells. In bone tissue, however, it acts as an agonist, mimicking the effects of estrogen and helping to maintain bone density. This dual action is characteristic of SERMs.

Clinical use

Trioxifene has been studied in clinical trials for the treatment of breast cancer and osteoporosis. However, it has not been approved for these indications by regulatory authorities such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

See also

• Selective estrogen receptor modulator
• Breast cancer
• Osteoporosis
• Tamoxifen
• Raloxifene

‎